The methionine (MET) dependency of tumor cells opens interesting perspectives for targeting tumor cells and potentiating chemotherapy treatment, like 5-fluorouracil (5-FU) and platinum compound. Since MET deprivation can individually potentiate the different chemotherapeutic agents used in the 48-hour combined regimen of 5-FU, leucovorin and oxaliplatin (FOLFOX) regimen, we initiated a feasibility study associating dietary MET restriction with the FOLFOX regimen in patients with metastatic colorectal cancer. Objectives: (i) To evaluate the depletion in the plasma MET concentration, and (ii) to assess the feasibility of this combination. Methods: Eleven patients were enrolled in this study. They received a median number of 3 two-week cycles of a MET-free diet (3 consecutive days) and FOLFOX6 regimen. Results: The plasma MET concentration was reduced by dietary MET restriction, with a depletion of 58% on the 1st day of MET-free diet. Indeed, we demonstrated the feasibility and good tolerance (nutritional status and toxicity) of the association of a MET-free diet with the FOLFOX regimen. Despite good compliance to the diet, this study revealed the difficulty of administering this combination during further months. Among the 4 patients evaluable for response, 3 experienced a partial response and 1 patient a disease stabilization.

Keywords:
Methionine-free diet, Metastatic colorectal cancer, Fluorouracil, Leucovorin, Oxaliplatine, FOLFOX
1.
Halpern BC, Clark BR, Hardy DN, Halpern RM, Smith RA: The effect of replacement of MET by homocystine on survival of malignant and normal adult mammalian cells in culture. Proc Natl Acad Sci USA 1974;71:1133–1136.
2.
Stern PH, Hoffman RM: Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst 1986;76:629–639.
3.
Breillout F, Antoine E, Poupon MF: MET dependency of malignant tumors: a possible approach for therapy. J Natl Cancer Inst 1990;82:1628–1632.
4.
Guo HY, Herrera H, Groce A, Hoffman RM: Expression of the biochemical defect of methionine dependence in fresh patient tumors in primary histoculture. Cancer Res 1993;53:2479–2483.
5.
Hoffman RM: Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis. A review and synthesis. Biochim Biophys Acta 1984;738:49–87.
6.
Cellarier E, Durando X, Vasson MP, Farges MC, Demiden A, Maurizis JC, Madelmont JC, Chollet P: Methionine dependency and cancer treatment. Cancer Treat Rev 2003;29:489–499.
7.
Guo H, Lishko VK, Herrera H, Groce A, Kubota T, Hoffman RM: Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. Cancer Res 1993;53:5676–5679.
8.
Poirson-Bichat F, Lopez R, Bras Goncalves RA, Miccoli L, Bourgeois Y, Demerseman P, Poisson M, Dutrillaux B, Poupon MF: Methionine deprivation and methionine analogs inhibit cell proliferation and growth of human xenografted gliomas. Life Sci 1997;60:919–931.
9.
Kreis W, Goodenow M: Methionine requirement and replacement by homocysteine in tissue cultures of selected rodent and human malignant and normal cells. Cancer Res 1978;38:2259–2262.
10.
Hoshiya Y, Kubota T, Inada T, Kitajima M, Hoffman RM: Methionine-depletion modulates the efficacy of 5-fluorouracil in human gastric cancer in nude mice. Anticancer Res 1997;17:4371–4375.
11.
Goseki N, Endo M: Thiol depletion and chemosensitization on nimustine hydrochloride by methionine-depleting total parenteral nutrition. Tohoku J Exp Med 1990;161:227–239.
12.
Yoshioka T, Wada T, Uchida N, Maki H, Yoshida H, Ide N, Kasai H, Hojo K, Shono K, Maekawa R, Yagi S, Hoffman RM, Sugita K: Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res 1998;58:2583–2587.
13.
Machover D, Zittoun J, Broet P, Metzger G, Orrico M, Goldschmidt E, Schilf A, Tonetti C, Tan Y, Delmas-Marsalet B, Luccioni C, Falissard B, Hoffman RM: Cytotoxic synergism of methioninase in combination with 5-fluorouracil and folinic acid. Biochem Pharmacol 2001;61:867–876.
14.
Goseki N, Yamazaki S, Shimojyu K, Kando F, Maruyama M, Endo M, Koike M, Takahashi H: Synergistic effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on human gastric cancer: a randomized, prospective clinical trial. Jpn J Cancer Res 1995;86:484–489.
15.
Poirson-Bichat F, Goncalves RA, Miccoli L, Dutrillaux B, Poupon MF: Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts. Clin Cancer Res 2000;6:643–653.
16.
Tan Y, Sun X, Xu M, Tan X, Sasson A, Rashidi B, Han Q, Tan X, Wang X, An Z, Sun FX, Hoffman RM: Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res 1999;5:2157–2163.
17.
Hoshiya Y, Kubota T, Matsuzaki SW, Kitajima M, Hoffman RM: Methionine starvation modulates the efficacy of cisplatin on human breast cancer in nude mice. Anticancer Res 1996;16:3515–3517.
18.
Goldberg RM: Advances in the treatment of metastatic colorectal cancer. Oncologist 2005;10:40–48.
19.
Minet-Quinard R, Van Praagh I, Kwiatkowski F, Beaujon G, Feillel V, Beaufrere B, Bargnoux PJ, Cynober L, Vasson MP: Pre- and postoperative aminoacidemia in breast cancer: a study vs. matched healthy subjects. Cancer Invest 2004;22:203–210.
20.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al: New guideline to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United Stats, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216.
21.
Kwiatkowski F, Girard M, Hacene K, Berlie J: Sem: a suitable statistical software adaptated for research in oncology (in French). Bull Cancer 2000;10:715–721.
22.
Lakshmanan FL, Perera WD, Scrimshaw NS, Young VR: Plasma and urinary amino acids and selected sulfur metabolites in young men fed a diet devoid of methionine and cystine. Am J Clin Nutr 1976;29:1367–1371.
23.
Epner DE, Morrow S, Wilcox M, Houghton JL: Nutrient intake and nutritional indexes in adults with metastatic cancer on a phase I clinical trial of dietary methionine restriction. Nutr Cancer 2002;42:158–166.
24.
Durando X, Thivat E, Farges MC, Cellarier E, D’Incan M, Demidem A,Vasson MP, Barthomeuf C, Chollet P: Optimal methionine-free diet duration for nitrosourea treatment: a phase I clinical trial. Nutr Cancer 2008;60:23–30.
25.
Sun X, Yang Z, Li S, Tan Y, Zhang N, Wang X, Yagi S, Yoshioka T, Takimoto A, Mitsushima K, Suginaka A, Frenkel EP, Hoffman RM: In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5′-phosphate supplementation. Cancer Res 2003;63:8377–8383.
26.
Yang Z, Wang J, Yoshioka T, Li B, Lu Q, Li S, Sun X, Tan Y, Yagi S, Frenkel EP, Hoffman RM: Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates. Clin Cancer Res 2004;10:2131–2138.
27.
Yang Z, Sun X, Li S, Tan Y, Wang X, Zhang N, Yagi S, Takakura T, Kobayashi Y, Takimoto A, Yoshioka T, Suginaka A, Frenkel EP, Hoffman RM: Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5′-phosphate. Cancer Res 2004;64:5775–5778.
28.
Yang Z, Wang J, Lu Q, Xu J, Kobayashi Y, Takakura T, Takimoto A, Yoshioka T, Lian C, Chen C, Zhang D, Zhang Y, Li S, Sun X, Tan Y, Yagi S, Frenkel EP, Hoffman RM: PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res 2004;64:6673–6678.
29.
Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–237.
30.
Leung FW: Etiologic factors of chronic constipation: review of the scientific evidence. Dig Dis Sci 2007;52:313–316.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.